查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108046

2035年前先進基因編輯技術市場進行分析和預測：按類型、產品、服務、技術、組件、應用、流程、最終用戶、解決方案和階段分類。

Advanced Gene Editing Technologies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球先進基因編輯技術市場預計將從2025年的52億美元成長到2035年的124億美元，複合年成長率（CAGR）為8.9%。這一成長主要得益於精準醫療需求的不斷成長、CRISPR技術的進步以及生物技術研發投入的增加。先進基因編輯技術市場集中度適中，CRISPR-Cas9技術佔主導地位，其次是TALENs和鋅指核酸酶。農業、生物醫學研究、治療藥物開發和精準醫療等領域的應用不斷拓展，是推動市場成長的主要因素。基因編輯平台的持續進步促進了研究機構、生物技術公司和臨床機構對該技術的日益重視。市場競爭格局既包括成熟的全球性企業，也包括透過技術創新、產品開發和策略聯盟競爭的創新區域企業。生物技術公司、學術機構、製藥公司和研究機構之間的合作正在加速先進基因療法、農業創新和下一代基因組編輯解決方案的開發。

按類型分類，先進基因編輯技術市場可分為CRISPR-Cas9、TALEN、鋅指核酸酶、Meganucleases、鹼基編輯、先導編輯和其他技術。其中，CRISPR-Cas9憑藉其高精度、具成本效益、易用性以及在科學研究和治療應用中的廣泛應用，佔了最大的市場佔有率。鹼基編輯和先導編輯技術正迅速崛起，因為它們能夠在不造成DNA雙鏈的情況下引入精確的基因修飾。同時，TALEN和鋅指核酸酶繼續用於需要高特異性的特殊應用，而Meganucleases和其他技術則用於小眾研究和臨床應用。

市場區隔
類型 CRISPR-Cas9、TALEN、鋅指核酸酶、Meganucleases、鹼基編輯、先導編輯等​​。
產品 試劑盒、試劑、儀器、軟體及其他
服務 基因編輯服務、客製化檢測開發、諮詢服務等。
科技 基因組編輯、基因靜默、基因擴增及其他
成分 酵素、引導RNA、供體DNA模板及其他
目的 生物醫學研究、農業生物技術、藥物研發、基因治療、診斷等領域。
過程 體內基因編輯、體外基因編輯及其他
最終用戶 生技公司、製藥公司、學術研究機構、受託研究機構及其他
解決方案 現成解決方案、客製化解決方案及其他
步 藥物發現、臨床前研究、臨床試驗、商業化等領域。

根據應用領域，先進基因編輯技術市場可細分為生物醫學研究、農業生物技術、藥物研發、基因治療、診斷及其他領域。其中，生物醫學研究佔最大佔有率，這得益於基因編輯工具在功能基因組學、疾病建模和目標檢驗研究中的廣泛應用。由於精準醫療投資的增加以及基於基因編輯的臨床試驗數量的成長，藥物研發和基因治療領域正經歷顯著成長。此外，隨著基因編輯技術在作物改良、疾病檢測和創新分子診斷解決方案開發的應用，農業生物技術和診斷領域也持續擴張。

區域概覽

北美在先進基因編輯技術市場佔主導地位，這得益於其對生物技術創新的巨額投資、先進的醫療保健基礎設施，以及眾多領先企業在CRISPR、TALEN、鋅指核酸酶和鹼基編輯技術開發方面的實力。政府對基因組研究的大力支持、積極的臨床試驗計畫以及研究機構與製藥公司之間的合作，正在加速基因編輯技術的商業化。精準醫療、細胞和基因治療以及農業生物技術等領域的應用需求不斷成長，進一步推動了市場發展。持續的技術進步、有利的研究法規環境以及大量的創業投資資金籌措，使北美成為最大的區域市場。

亞太地區預計將成為先進基因編輯技術市場成長最快的地區，這主要得益於生物技術研究投入的增加、基因組醫學舉措的拓展以及生命科學基礎設施的快速發展。中國、日本、韓國、新加坡和印度等國政府正透過資助計畫和研究合作支持基因編輯創新。臨床研究活動的活性化、對個人化醫療需求的成長以及先進分子技術的廣泛應用正在推動市場擴張。強大的生物技術製造能力、不斷提升的科學專業知識以及支持創新的政策預計將維持全部區域的快速成長。

主要趨勢和促進因素

高精度基因編輯平台的出現正在擴大其治療應用範圍。

CRISPR、鹼基編輯、先導編輯和表觀基因編輯等先進基因編輯技術的持續創新正在改變市場格局。與傳統方法相比，這些技術具有更高的編輯精度、更佳的安全性以及更高的效率。研究人員正持續開發精密的遞送系統和自動化基因組工程平台，以支援其在醫療保健、農業、工業生物技術和細胞治療等領域的應用。這種持續的技術進步正在擴大基因編輯在研究和商業應用方面的範圍。

對精準醫療投入的增加正在推動市場成長：

精準醫療和個人化治療的日益普及是推動先進基因編輯技術市場發展的主要動力。遺傳性疾病、癌症和罕見疾病的日益普遍，促使人們對能夠精確修飾致病基因的技術需求不斷成長。生物技術投資的增加、對先進療法的監管支持、產學研合作的加強以及研究經費的增加，都在加速創新和商業化進程，從而促進全球市場的永續成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • CRISPR-Cas9
    • TALEN
    • 鋅指核酸酶
    • Meganucleases
    • 基礎編輯
    • Prime Edit
    • 其他
  • 市場規模及預測：依產品分類
    • 成套工具
    • 試劑
    • 裝置
    • 軟體
    • 其他
  • 市場規模及預測：依服務分類
    • 基因編輯服務
    • 客製化檢測開發
    • 諮詢服務
    • 其他
  • 市場規模及預測：依技術分類
    • 基因組編輯
    • 基因靜默
    • 基因擴增
    • 其他
  • 市場規模及預測：依應用領域分類
    • 生物醫學研究
    • 農業生物技術
    • 藥物發現
    • 基因治療
    • 診斷
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術研究機構
    • 受託研究機構
    • 其他
  • 市場規模及預測：依製程分類
    • 體內基因編輯
    • 體外基因編輯
    • 其他
  • 市場規模及預測：依組件分類
    • 酵素
    • 引導RNA
    • 供體DNA模板
    • 其他
  • 市場規模及預測：按解決方案分類
    • 現成的解決方案
    • 客製化解決方案
    • 其他
  • 市場規模及預測：依階段分類
    • 藥物發現
    • 臨床前
    • 臨床試驗
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Thermo Fisher Scientific
  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Beam Therapeutics
  • Precision BioSciences
  • Cellectis
  • Horizon Discovery
  • Caribou Biosciences
  • Inscripta
  • Mammoth Biosciences
  • Synthego
  • GenScript
  • Integrated DNA Technologies
  • Origene Technologies
  • Bluebird Bio
  • Recombinetics
  • Poseida Therapeutics
  • Graphite Bio

第9章 關於我們

簡介目錄
Product Code: GIS32885

The global Advanced Gene Editing Technologies Market is projected to grow from $5.2 billion in 2025 to $12.4 billion by 2035, at a compound annual growth rate (CAGR) of 8.9%. Growth is driven by increased demand for precision medicine, advancements in CRISPR technology, and rising investments in biotechnology research and development. The Advanced Gene Editing Technologies Market is moderately consolidated, with CRISPR-Cas9 emerging as the leading technology, followed by TALENs and zinc finger nucleases. The market is driven by expanding applications in agriculture, biomedical research, therapeutic development, and precision medicine. Growing adoption across research laboratories, biotechnology companies, and clinical institutions is supported by continuous advancements in gene editing platforms. The competitive landscape includes established global companies alongside innovative regional players competing through technological innovation, product development, and strategic collaborations. Partnerships between biotechnology firms, academic institutions, pharmaceutical companies, and research organizations are accelerating the development of advanced gene therapies, agricultural innovations, and next-generation genome editing solutions.

Based on the Type segment, the Advanced Gene Editing Technologies Market is segmented into CRISPR-Cas9, TALENs, Zinc Finger Nucleases, Meganucleases, Base Editing, Prime Editing, and Others. Among these, CRISPR-Cas9 holds the largest market share due to its high precision, cost-effectiveness, ease of use, and widespread adoption across research and therapeutic applications. Base Editing and Prime Editing are emerging rapidly, driven by their ability to introduce precise genetic modifications without creating double-strand DNA breaks. Meanwhile, TALENs and Zinc Finger Nucleases continue to be utilized in specialized applications requiring high specificity, while meganucleases and other technologies serve niche research and clinical use cases.

Market Segmentation
TypeCRISPR-Cas9, TALENs, Zinc Finger Nucleases, Meganucleases, Base Editing, Prime Editing, Others
ProductKits, Reagents, Instruments, Software, Others
ServicesGene Editing Services, Custom Assay Development, Consulting Services, Others
TechnologyGenome Editing, Gene Silencing, Gene Amplification, Others
ComponentEnzymes, Guide RNA, Donor DNA Templates, Others
ApplicationBiomedical Research, Agricultural Biotechnology, Drug Development, Gene Therapy, Diagnostics, Others
ProcessIn Vivo Gene Editing, Ex Vivo Gene Editing, Others
End UserBiotechnology Companies, Pharmaceutical Companies, Academic Research Institutes, Contract Research Organizations, Others
SolutionsOff-the-Shelf Solutions, Customized Solutions, Others
StageDiscovery, Preclinical, Clinical Trials, Commercialization, Others

Based on the Application segment, the Advanced Gene Editing Technologies Market is segmented into Biomedical Research, Agricultural Biotechnology, Drug Development, Gene Therapy, Diagnostics, and Others. Among these, Biomedical Research accounts for the largest share, supported by the extensive use of gene editing tools in functional genomics, disease modeling, and target validation studies. Drug Development and Gene Therapy are witnessing significant growth owing to increasing investments in precision medicine and the rising number of gene-editing-based clinical trials. Additionally, agricultural biotechnology and diagnostics continue to expand as gene editing enables crop improvement, disease detection, and the development of innovative molecular diagnostic solutions.

Geographical Overview

North America dominates the advanced gene editing technologies market owing to substantial investments in biotechnology innovation, advanced healthcare infrastructure, and the presence of leading companies developing CRISPR, TALEN, zinc finger nuclease, and base-editing technologies. Strong government support for genomic research, active clinical trial programs, and collaborations between research institutions and pharmaceutical companies accelerate commercialization. Growing demand for precision medicine, cell and gene therapies, and agricultural biotechnology applications further strengthens market growth. Continuous technological advancements, favorable regulatory pathways for research, and significant venture capital funding position North America as the largest regional market.

Asia-Pacific is expected to experience the fastest growth in the advanced gene editing technologies market due to increasing investments in biotechnology research, expanding genomic medicine initiatives, and rapid development of life sciences infrastructure. Governments across China, Japan, South Korea, Singapore, and India are supporting gene-editing innovation through funding programs and research collaborations. Rising clinical research activities, increasing demand for personalized therapies, and growing adoption of advanced molecular technologies are driving market expansion. Strong biotechnology manufacturing capabilities, expanding scientific expertise, and supportive innovation policies are expected to sustain high growth across the region.

Key Trends and Drivers

Emergence of Highly Precise Gene Editing Platforms Is Expanding Therapeutic Applications:

Continuous innovation in advanced gene editing technologies, including CRISPR, base editing, prime editing, and epigenome editing, is reshaping the market. These technologies provide greater editing accuracy, improved safety profiles, and enhanced efficiency compared to earlier approaches. Researchers are increasingly developing sophisticated delivery systems and automated genome engineering platforms to support applications in healthcare, agriculture, industrial biotechnology, and cell therapy. Ongoing technological advancements are broadening the scope of gene editing across research and commercial applications.

Increasing Investment in Precision Medicine Is Driving the Market Growth:

The growing focus on precision medicine and personalized therapies is a major driver of the advanced gene editing technologies market. Rising prevalence of inherited disorders, cancer, and rare diseases has increased demand for technologies capable of modifying disease-causing genes with high precision. Expanding biotechnology investments, favorable regulatory support for advanced therapies, increasing academic-industry collaborations, and rising research funding are accelerating innovation and commercialization, contributing to sustained growth in the global market.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 CRISPR-Cas9
    • 4.1.2 TALENs
    • 4.1.3 Zinc Finger Nucleases
    • 4.1.4 Meganucleases
    • 4.1.5 Base Editing
    • 4.1.6 Prime Editing
    • 4.1.7 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Kits
    • 4.2.2 Reagents
    • 4.2.3 Instruments
    • 4.2.4 Software
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Editing Services
    • 4.3.2 Custom Assay Development
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Genome Editing
    • 4.4.2 Gene Silencing
    • 4.4.3 Gene Amplification
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Biomedical Research
    • 4.5.2 Agricultural Biotechnology
    • 4.5.3 Drug Development
    • 4.5.4 Gene Therapy
    • 4.5.5 Diagnostics
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo Gene Editing
    • 4.7.2 Ex Vivo Gene Editing
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Enzymes
    • 4.8.2 Guide RNA
    • 4.8.3 Donor DNA Templates
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Off-the-Shelf Solutions
    • 4.9.2 Customized Solutions
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Discovery
    • 4.10.2 Preclinical
    • 4.10.3 Clinical Trials
    • 4.10.4 Commercialization
    • 4.10.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Solutions
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Solutions
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Solutions
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Solutions
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Solutions
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Solutions
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Solutions
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Solutions
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Solutions
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Solutions
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Solutions
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Solutions
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Solutions
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Solutions
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Solutions
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Solutions
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Solutions
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Solutions
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Solutions
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Solutions
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Solutions
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Solutions
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Solutions
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Solutions
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Thermo Fisher Scientific
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 CRISPR Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Editas Medicine
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Intellia Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Sangamo Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Beam Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Precision BioSciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cellectis
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Horizon Discovery
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Caribou Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Inscripta
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Mammoth Biosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Synthego
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 GenScript
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Integrated DNA Technologies
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Origene Technologies
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bluebird Bio
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Recombinetics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Poseida Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Graphite Bio
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us